Breaking News Instant updates and real-time market news.

ESPR

Esperion

$12.32

-0.58 (-4.50%)

07:40
10/13/16
10/13
07:40
10/13/16
07:40

Esperion says bempedoic acid Phase 3 program to include any statin at any dose

Esperion announced the bempedoic acid global pivotal Phase 3 LDL-C lowering clinical development program will include patients with hypercholesterolemia on any statin at any dose based on positive top-line results from its Phase 2 pharmacokinetics and pharmacodynamics study of bempedoic acid added to atorvastatin 80 mg, and the previously completed Phase 1 and Phase 2 studies.

  • 06

    Nov

ESPR Esperion
$12.32

-0.58 (-4.50%)

06/29/16
06/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. HeartWare (HTWR) downgraded to Equal Weight from Overweight at Barclays by analyst Matthew Taylor, saying he does not expect a competing takeover bid to Medtronic's (MDT) offer. The analyst raised his price target for the shares to $58 from $35. Similarly, shares were downgraded to Market Perform from Outperform at Wells Fargo, with analyst Larry Biegelsen saying he sees a low likelihood that a higher bidder will emerge. The analyst believes Medtronic paid a fair valuation for HeartWare. HeartWare was also downgraded to Neutral from Buy at BTIG. 2. Esperion (ESPR) downgraded to Neutral from Overweight at JPMorgan by analyst Jessica Fye, who slashed her price target for shares to $15 from $50. The analyst says last night's regulatory update is a net negative. Disappointingly, the FDA did not sign off on the use of LDL-C lowering as an acceptable regulatory endpoint for approval of bempedoic acid for the treatment of statin-intolerant patients, Fye tells investors in a research note. The analyst still believes bempedoic acid is an effective LDL-C lowering agent, but now sees a drawn out path to approval in the U.S. Esperion was also downgraded to Underperform at Neutral at Credit Suisse by analyst Vamil Divan, who says the update on the development plans for bempedoic acid leaves him increasingly concerned about the products outlook in the U.S. market. The analyst was surprised that the FDA may not be willing to allow LDL-C as a surrogate endpoint for initial approval but believes there will be significant pressure, and limited upside, on shares until that certainty is obtained, and that process may take years to play out. Esperion was also downgraded to Sector Perform from Outperform at RBC Capital. 3. Comerica (CMA) downgraded to Underperform from Neutral at BofA/Merrill, which reduced its price target to $36 from $45. The firm's analyst lowered estimates 8% below consensus for 2016 and 17% below consensus in 2017 due to low rates that will pressure spread revenue growth, slower U.S. economic growth, and continued reserve build. The firm also downgraded Regions Financial (RF), Synovus (SNV), Texas Capital (TCBI) and Franklin Financial Network (FSB) to Neutral from Buy, as well as Zions Bancorp (ZION) to Underperform from Neutral. 4. comScore (SCOR) downgraded to Neutral from Positive at Susquehanna, citing uncertainty surrounding its accounting issues. The firm continues to like the long-term fundamental story, but with an unclear timeline for its resolution, they are moving to the sidelines. Susquehanna lowered its price target to $18 from $30 on comScore shares. 5. Harman (HAR) downgraded to Sector Perform from Outperform at RBC Capital partly based on the low number of new car launches next year, the firm's forecast for reduced production by the company's European customers, and the firm's reduction in its U.S. auto production versus its previous forecast. Additionally, the firm expects GM (GM) to delay a number of its connected car launches that had been slated for fiscal 2017 until fiscal 2018. The firm lowered its price target to $73 from $85. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/16
LEHM
06/29/16
DOWNGRADE
LEHM
Equal Weight
Esperion downgraded to Equal Weight from Overweight at Barclays
07/05/16
UBSW
07/05/16
DOWNGRADE
Target $11
UBSW
Neutral
Esperion downgraded to Neutral from Buy at UBS
UBS analyst Jeffrey Hung downgraded Esperion Therapeutics to Neutral citing an uncertain U.S. regulatory pathway after the FDA did not specifically state that LDL-lowering data could be used for accelerated approval. The analyst cut his price target for the shares to $11 from $69.
07/05/16
WBTH
07/05/16
DOWNGRADE
WBTH
Hold
Esperion downgraded to Hold from Buy at WallachBeth (pre-open)

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$250.06

0.09 (0.04%)

08:17
09/21/17
09/21
08:17
09/21/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$25.40

0.15 (0.59%)

08:17
09/21/17
09/21
08:17
09/21/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$91.37

-1.23 (-1.33%)

08:17
09/21/17
09/21
08:17
09/21/17
08:17
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTK

Paratek Pharmaceuticals

$24.85

0.6 (2.47%)

08:16
09/21/17
09/21
08:16
09/21/17
08:16
Hot Stocks
Paratek Pharmaceuticals omadacycline receives QIDP designation from FDA »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 17

    Oct

QQQ

PowerShares QQQ Trust

$145.35

-0.45 (-0.31%)

08:16
09/21/17
09/21
08:16
09/21/17
08:16
Technical Analysis
PowerShares QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

08:16
09/21/17
09/21
08:16
09/21/17
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:16
09/21/17
09/21
08:16
09/21/17
08:16
Conference/Events
Washington Association of Money Managers to hold a meeting »

Michael Mandel, Chief…

NDX

Nasdaq 100 Index

$5,973.60

-17.47345 (-0.29%)

08:16
09/21/17
09/21
08:16
09/21/17
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDS

FactSet

08:15
09/21/17
09/21
08:15
09/21/17
08:15
Upgrade
FactSet rating change  »

FactSet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

08:15
09/21/17
09/21
08:15
09/21/17
08:15
General news
Jobless Claims to be reported at 08:30 »

Week of 9/16 Jobless…

08:15
09/21/17
09/21
08:15
09/21/17
08:15
General news
Philadelphia Fed Business Outlook Survey General Conditions Index to be reported at 08:30 »

September Philadelphia…

AMD

AMD

$13.74

0.62 (4.73%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

08:14
09/21/17
09/21
08:14
09/21/17
08:14
Recommendations
AMD, Tesla, Nvidia analyst commentary  »

Working with Tesla would…

AMD

AMD

$13.74

0.62 (4.73%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AZUL

Azul

$28.59

0.07 (0.25%)

, EADSY

Airbus

$22.29

0.09 (0.41%)

08:14
09/21/17
09/21
08:14
09/21/17
08:14
Hot Stocks
Azul orders five Airbus A330-900neo aircraft for international flights »

Azul (AZUL) announced an…

AZUL

Azul

$28.59

0.07 (0.25%)

EADSY

Airbus

$22.29

0.09 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNRX

VolitionRx

$2.72

-0.03 (-1.09%)

08:12
09/21/17
09/21
08:12
09/21/17
08:12
Conference/Events
Microcap Club to hold a summit »

MicroCap Leadership…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

FNF

FNF Group

$48.30

-0.13 (-0.27%)

, FNFV

FNFV

$17.35

0.25 (1.46%)

08:11
09/21/17
09/21
08:11
09/21/17
08:11
Conference/Events
Stephens to hold a field trip »

Jacksonville Investor…

FNF

FNF Group

$48.30

-0.13 (-0.27%)

FNFV

FNFV

$17.35

0.25 (1.46%)

BKFS

Black Knight Financial

$44.00

-0.1 (-0.23%)

FIS

FIS

$92.80

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 27

    Sep

ITUS

ITUS

$1.93

0.0101 (0.53%)

08:10
09/21/17
09/21
08:10
09/21/17
08:10
Hot Stocks
ITUS provides update on cancer detection technology, new CAR-T initiative »

ITUS provides a corporate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.51

-0.17 (-0.09%)

08:10
09/21/17
09/21
08:10
09/21/17
08:10
Initiation
Netflix initiated  »

Netflix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    Oct

  • 22

    Oct

08:09
09/21/17
09/21
08:09
09/21/17
08:09
Conference/Events
Citigroup to hold a conference »

Asean Yield Focus…

SHO

Sunstone Hotel

$15.93

0.16 (1.01%)

08:08
09/21/17
09/21
08:08
09/21/17
08:08
Hot Stocks
Sunstone Hotel provides update on impact from Hurricanes Harvey Irma »

Sunstone Hotel provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$37.23

-2 (-5.10%)

08:07
09/21/17
09/21
08:07
09/21/17
08:07
Recommendations
L Brands analyst commentary  »

Victoria's Secret…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.74

0.62 (4.73%)

, NVDA

Nvidia

$185.84

-1.51 (-0.81%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
AMD, Nvidia, Tesla analyst commentary  »

Tesla shift to AMD from…

AMD

AMD

$13.74

0.62 (4.73%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ALNY

Alnylam

$113.84

38.8 (51.71%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
Alnylam analyst commentary  »

Alnylam data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
09/21/17
09/21
08:05
09/21/17
08:05
General news
Canada wholesale trade report preview »

Canada wholesale trade…

BHGE

Baker Hughes

$37.50

0.11 (0.29%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

SCG

Scana

$57.80

-0.41 (-0.70%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Hot Stocks
Scana receives subpoena for documents relating to nuclear project »

Scana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.